Uric acid and mental disorders
DOI: 10.32364/2587-6821-2023-7-7-9
O.V. Zhelyabina1, M.S. Eliseev1, D.N. Sosin2, M.E. Levin3
1V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation
2Russian Medical Academy of Continuous Professional Education, Moscow, Russian Federation
3City Clinical Hospital No. 67, Moscow, Russian Federation
Over the past 100 years, there has been a progressive increase in the level of serum uric acid (UA). Modern scientific data suggest that the impact of hyperuricemia (HU) goes beyond the classical gout manifestations. UA has both oxidant and antioxidant properties, which determines its multidirectional effect on the human body as a whole. High serum UA levels may be a sign of increased purine metabolism and decreased adenosine transmission. Currently, there is evidence concerning the impact of all purine metabolism components on the mental sphere. The article discusses the pathogenetic association of purine metabolism disorders with the mental disorders and the possibility of considering UA as one of the targets for drug therapy of mental disorders. The results of recent studies show that allopurinol can be an important drug therapy component in patients with mental disorders. Accessibility and a good safety profile can also be the basis for further drug studies regarding the prospects of its wide practical use in patients with mental disorders and HU.
Keywords: uric acid, mental disorders, depression, adenosine, xanthine oxidase, allopurinol.
For citation: Zhelyabina O.V., Eliseev M.S., Sosin D.N., Levin M.E. Uric acid and mental disorders. Russian Medical Inquiry. 2023;7(7):460–466 (in Russ.). DOI: 10.32364/2587-6821-2023-7-7-9.
About the authors:
Olga V. Zhelyabina — Junior Researcher at the Laboratory of Microcrystalline Arthritis, V.A. Nasonova Research Institute of Rheumatology; 34A, Kashirskoye road, Moscow, 115522, Russian Federation; ORCID iD 0000-0002-5394-7869.
Maxim S. Eliseev — C. Sc. (Med.), Head of the Laboratory of Microcrystalline Arthritis, V.A. Nasonova Research Institute of Rheumatology; 34A, Kashirskoye road, Moscow, 115522, Russian Federation; ORCID iD 0000-0003-1191-5831.
Dmitry N. Sosin — C. Sc. (Med.), Associate Professor of the Department of Psychiatry, Russian Medical Academy of Continuous Professional Education; 2/1, Barrikadnaya str., Moscow, 125993, Russian Federation; ORCID iD 0000-0002-2314-7174.
Mikhail E. Levin — Head of the Psychiatric Service, City Clinical Hospital No. 67; 2/44, Salyama Adilya str., Moscow, 123423, Russian Federation; ORCID iD 0000-0002-9197-1691.
Contact information: Maxim S. Eliseev, e-mail: elicmax@yandex.ru.
Financial Disclosure: The work was performed as part of a fundamental scientific research "Research and development of an interdisciplinary individual care model for patients with autoinflammatory degenerative disorders (osteoarthritis, osteoporosis, sarcopenia, gout, calcium pyrophosphate deposition) and multimorbidity (obesity, cardiovascular diseases)". No. 1021051403074-2.
There is no conflict of interest.
Received 30.06.2023.
Revised 21.07.2023.
Accepted 11.08.2023.
2. Crawley W.T., Jungels C.G., Stenmark K.R. et al. U-shaped association of uric acid to overall-cause mortality and its impact on clinical management of hyperuricemia. Redox Biol. 2022;51:102271. DOI: 10.1016/j.redox.2022.102271.
3. Yip K., Cohen R.E., Pillinger M.H. Asymptomatic hyperuricemia: is it really asymptomatic? Curr Opin Rheumatol. 2020;32(1):71–79. DOI: 10.1097/BOR.0000000000000679.
4. Sautin Y.Y., Johnson R.J. Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids. 2008;27(6):608–619. DOI: 10.1080/15257770802138558.
5. Krügel U. Purinergic receptors in psychiatric disorders. Neuropharmacology. 2016;104:212–225. DOI: 10.1016/j.neuropharm.2015.10.032.
6. Burnstock G. Purinergic signalling and disorders of the central nervous system. Nat Rev Drug Discov. 2008;7(7):575–590. DOI: 10.1038/nrd2605.
7. Furuhashi M. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity. Am J Physiol Endocrinol Metab. 2020;319(5):E827–E834. DOI: 10.1152/ajpendo.00378.2020.
8. Joosten L.A.B., Crişan T.O., Bjornstad P. et al. Asymptomatic hyperuricaemia: a silent activator of the innate immune system. Nat Rev Rheumatol. 2020;16(2):75–86. DOI: 10.1038/s41584-019-0334-3.
9. Martorell M., Lucas X., Alarcón-Zapata P. et al. Targeting Xanthine Oxidase by Natural Products as a Therapeutic Approach for Mental Disorders. Curr Pharm Des. 2021;27(3):367–382. DOI: 10.2174/1381612826666200621165839.
10. Savio L.E.B., Leite-Aguiar R., Alves V.S. et al. Purinergic signaling in the modulation of redox biology. Redox Biol. 2021;47:102137. DOI: 10.1016/j.redox.2021.102137.
11. CADE J.F. Lithium salts in the treatment of psychotic excitement. Med J Aust. 1949;2(10):349–352. DOI: 10.1080/j.1440-1614.1999.06241.x.
12. Chen J.F., Lee C.F., Chern Y. Adenosine receptor neurobiology: overview. Int Rev Neurobiol. 2014;119:1–49. DOI: 10.1016/B978-0-12-801022-8.00001-5.
13. Squadrito G.L., Cueto R., Splenser A.E. et al. Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys. 2000;376(2):333–337. DOI: 10.1006/abbi.2000.1721.
14. Kesebir S., Koc M.I., Yosmaoglu A. Bipolar Spectrum Disorder May Be Associated With Family History of Diseases. J Clin Med Res. 2020;12(4):251–254. DOI: 10.14740/jocmr4143.
15. Singer P., Yee B.K. The adenosine hypothesis of schizophrenia into its third decade: From neurochemical imbalance to early life etiological risks. Front Cell Neurosci. 2023;17:1120532. DOI: 10.3389/fncel.2023.1120532.
16. Freund N., Juckel G. Bipolar Disorder: Its Etiology and How to Model in Rodents. Methods Mol Biol. 2019;2011:61–77. DOI: 10.1007/978-1-4939-9554-7_4.
17. Bartoli F., Crocamo C., Mazza M.G. et al. Uric acid levels in subjects with bipolar disorder: A comparative meta-analysis. J Psychiatr Res. 2016;81:133–139. DOI: 10.1016/j.jpsychires.2016.07.007.
18. Gubert C., Jacintho Moritz C.E., Vasconcelos-Moreno M.P. et al. Peripheral adenosine levels in euthymic patients with bipolar disorder. Psychiatry Res. 2016;246:421–426. DOI: 10.1016/j.psychres.2016.10.007.
19. Akhondzadeh S., Milajerdi M.R., Amini H. et al. Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial. Bipolar Disord. 2006;8(5 Pt 1):485–489. DOI: 10.1111/j.1399-5618.2006.00363.x.
20. Machado-Vieira R., Soares J.C., Lara D.R. et al. A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. J Clin Psychiatry. 2008;69(8):1237–1245. DOI: 10.4088/jcp.v69n0806.
21. Jahangard L., Soroush S., Haghighi M. et al. In a double-blind, randomized and placebo-controlled trial, adjuvant allopurinol improved symptoms of mania in in-patients suffering from bipolar disorder. Eur Neuropsychopharmacol. 2014;24(8):1210–1221. DOI: 10.1016/j.euroneuro.2014.05.013.
22. Charlson F.J., Ferrari A.J., Santomauro D.F. et al. Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016. Schizophr Bull. 2018;44(6):1195–1203. DOI: 10.1093/schbul/sby058.
23. Boison D., Singer P., Shen H.Y. et al. Adenosine hypothesis of schizophrenia-opportunities for pharmacotherapy. Neuropharmacology. 2012;62(3):1527–1543. DOI: 10.1016/j.neuropharm.2011.01.048.
24. Connor M. Allopurinol for pain relief: more than just crystal clearance? Br J Pharmacol. 2009;156(1):4–6. DOI: 10.1111/j.1476-5381.2008.00065.x.
25. Lintunen J., Lähteenvuo M., Tiihonen J. et al. Adenosine modulators and calcium channel blockers as add-on treatment for schizophrenia. NPJ Schizophr. 2021;7(1):1. DOI: 10.1038/s41537-020-00135-y.
26. Hirota T., Kishi T. Adenosine hypothesis in schizophrenia and bipolar disorder: a systematic review and meta-analysis of randomized controlled trial of adjuvant purinergic modulators. Schizophr Res. 2013;149(1–3):88–95. DOI: 10.1016/j.schres.2013.06.038.
27. Aldaba-Muruato L.R., Moreno M.G., Shibayama M. et al. Protective effects of allopurinol against acute liver damage and cirrhosis induced by carbon tetrachloride: modulation of NF-κB, cytokine production and oxidative stress. Biochim Biophys Acta. 2012;1820(2):65–75. DOI: 10.1016/j.bbagen.2011.09.018.
28. Olah T., Regely K., Mandi Y. The inhibitory effects of allopurinol on the production and cytotoxicity of tumor necrosis factor. Naunyn Schmiedebergs Arch Pharmacol 1994;350(1):96–99. DOI: 10.1007/BF00180017.
29. Wang W., Wang C., Ding X.-Q. et al. Quercetin and allopurinol reduce liver thioredoxin-interacting protein to alleviate inflammation and lipid accumulation in diabetic rats. Br J Pharmacol. 2013;169(6):1352–1371. DOI: 10.1111/bph.12226.
30. Terrone G., Balosso S., Pauletti A. et al. Inflammation and reactive oxygen species as disease modifiers in epilepsy. Neuropharmacology. 2020;167:107742. DOI: 10.1016/j.neuropharm.2019.107742.
31. Cerri C., Caleo M., Bozzi Y. Chemokines as new inflammatory players in the pathogenesis of epilepsy. Epilepsy Res. 2017;136:77–83. DOI: 10.1016/j.eplepsyres.2017.07.016.
32. Chen H.L., Hsu Y.C., Chen C.H. et al. Gout and the risk of epilepsy: A population-based cohort study. Medicine (Baltimore). 2020;99(26):e20823. DOI: 10.1097/MD.0000000000020823.
33. Greene R.W. Adenosine: front and center in linking nutrition and metabolism to neuronal activity. J Clin Invest. 2011;121(7):2548–2550. DOI: 10.1172/JCI58391.
34. Rahimi N., Modabberi S., Faghir-Ghanesefat H. et al. The possible role of nitric oxide signaling and NMDA receptors in allopurinol effect on maximal electroshock- and pentylenetetrazol-induced seizures in mice. Neurosci Lett. 2022;778:136620. DOI: 10.1016/j.neulet.2022.136620.
35. Togha M., Akhondzadeh S., Motamedi M. et al. Allopurinol as adjunctive therapy in intractable epilepsy: a double-blind and placebo-controlled trial. Arch Med Res. 2007;38(3):313–316. DOI: 10.1016/j.arcmed.2006.10.010.
36. Black C.N., Bot M., Scheffer P.G. et al. Is depression associated with increased oxidative stress? A systematic review and meta-analysis. Psychoneuroendocrinology. 2015;51:164–175. DOI: 10.1016/j.psyneuen.2014.09.025.
37. Palta P., Samuel L.J., Miller E.R. 3rd, Szanton S.L. Depression and oxidative stress: results from a meta-analysis of observational studies. Psychosom Med. 2014;76(1):12–19. DOI: 10.1097/PSY.0000000000000009.
38. Wen S., Cheng M., Wang H. et al. Serum uric acid levels and the clinical characteristics of depression. Clin Biochem. 2012;45(1–2):49–53. DOI: 10.1016/j.clinbiochem.2011.10.010.
39. Yang T., Nie Z., Shu H. et al. The Role of BDNF on Neural Plasticity in Depression. Front Cell Neurosci. 2020;14:82. DOI: 10.3389/fncel.2020.00082.
40. Francis K.T. Psychologic correlates of serum indicators of stress in man: a longitudinal study. Psychosom Med. 1979;41(8):617–628. DOI: 10.1097/00006842-197912000-00003.
41. Trevisan M., O'Leary E., Farinaro E. et al. Short- and long-term association between uric acid and a natural disaster. Psychosom Med. 1997;59(2):109–113. DOI: 10.1097/00006842-199703000-00001.
42. Fendri C., Mechri A., Khiari G. et al. Implication du stress oxydant dans la physiopathologie de la schizophrénie: revue de la littérature [Oxidative stress involvement in schizophrenia pathophysiology: a review]. Encephale. 2006;32(2 Pt 1):244–252 (in French.). DOI: 10.1016/s0013-7006(06)76151-6.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
